Enhanced p22phox expression impairs vascular function through p38 and ERK1/2 MAP kinase-dependent mechanisms in type 2 diabetic mice

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 306, Issue 7, 2014, Pages

  Kassan, Modar ^a,d   Choi, Soo Kyoung ^a,b   Galán, Maria ^a   Lee, Young Ho ^b   Trebak, Mohamed ^c   Matrougui, Khalid ^a,d  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Yonsei University College of Medicine   (South Korea)

^c STATE UNIVERSITY OF NEW YORK   (United States)

^d Eastern Virginia School of Medicine   (United States)

Author keywords

Endothelium dependent relaxation; NADPH; Type 2 diabetes

Indexed keywords

MACROGOL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; PEGORGOTEIN; PROTEIN P22; REACTIVE OXYGEN METABOLITE; SCAVENGER; SMALL INTERFERING RNA; SUPEROXIDE DISMUTASE; CYTOCHROME B; MAPK1 PROTEIN, MOUSE; P22(PHOX) PROTEIN, MOUSE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ARTERIOLE; ARTICLE; BLOOD VESSEL REACTIVITY; BODY WEIGHT; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIAL DYSFUNCTION; FEMORAL ARTERY; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SYSTOLIC BLOOD PRESSURE; VASCULAR ENDOTHELIUM; WESTERN BLOTTING; ANIMAL; CORONARY BLOOD VESSEL; DIABETIC ANGIOPATHY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; ENDOTHELIUM-DEPENDENT RELAXATION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; P22PHOX; PATHOPHYSIOLOGY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UPREGULATION; VASODILATATION;

ENDOTHELIUM-DEPENDENT RELAXATION; NADPH; P22PHOX; TYPE 2 DIABETES;

ANIMALS; CORONARY VESSELS; CYTOCHROME B GROUP; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FREE RADICAL SCAVENGERS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NADPH OXIDASE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RNA INTERFERENCE; RNA, SMALL INTERFERING; UP-REGULATION; VASODILATION; VASODILATOR AGENTS;

EID: 84900523078     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00872.2013     Document Type: Article

References (50)

1. Adaikalakoteswari A, Balasubramanyam M, Rema M, Mohan V. Differential gene expression of NADPH oxidase (p22phox) and hemoxygenase-1 in patients with Type 2 diabetes and microangiopathy. Diabet Med 23: 666-674, 2006.
2. Amamori T, Inanami O, Sumimoto H, Akasaki T, Nagahata H, Kuwabara M. Relationship between p38 mitogen-activated protein kinase and small GTPase Rac for the activation of NADPH oxidase in bovine neutrophils. Biochem Biophys Res Commun 293: 1571-1578, 2002.
3. Amara N, Bachoual R, Desmard M, Golda S, Guichard C, Lanone S, Aubier M, Ogier-Denis E, Boczkowski J. Diesel exhaust particles induce matrix metalloprotease-1 in human lung epithelial cells via a NADP(H) oxidase/NOX4 redox-dependent mechanism. Am J Physiol Lung Cell Mol Physiol 293: L170-L181, 2007.
4. Ambasta RK, Kumar P, Griendling KK, Schmidt HH, Busse R, Brandes RP. Direct interaction of the novel nox proteins with p22phox is required for the formation of a functionally active nadph oxidase. J Biol Chem 279: 45935-45941, 2004.
5. Arca M, Conti B, Montali A, Pignatelli P, Campagna F, Barilla F, Tanzilli G, Verna R, Vestri A, Gaudio C, Violi F. C242T polymorphism of NADPH oxidase p22phox and recurrence of cardiovascular events in coronary artery disease. Arterioscler Thromb Vasc Biol 28: 752-757, 2008.
6. Avogaro A, Albiero M, Menegazzo L, de Kreutzenberg S, Fadini GP. Endothelial dysfunction in diabetes: the role of reparatory mechanisms. Diabetes Care 34: S285-S290, 2011.
7. Avogaro A, Pagnin E, Calò L. Monocyte NADPH oxidase subunit p22(phox) and inducible hemeoxygenase-1 gene expressions are increased in type II diabetic patients: relationship with oxidative stress. J Clin Endocrinol Metab 88: 1753-1759, 2003.
8. Bao W, Behm DJ, Nerurkar SS, Ao Z, Bentley R, Mirabile RC, Johns DG, Woods TN, Doe CP, Coatney RW, Ohlstein JF, Douglas SA, Willette RN, Yue TL. Effects of p38 MAPK Inhibitor on angiotensin II-dependent hypertension, organ damage, and superoxide anion production. J Cardiovasc Pharmacol 49: 362-368, 2007.
9. Belmadani S, Palen DI, Gonzalez-Villalobos RA, Boulares HA, Matrougui K. Elevated epidermal growth factor receptor phosphorylation induces resistance artery dysfunction in diabetic db/db mice. Diabetes 57: 1629-1637, 2008.
10. Bhunia AK, Han H, Snowden A, Chatterjee S. Redox-regulated signaling by lactosylceramide in the proliferation of human aortic smooth muscle cells. J Biol Chem 272: 15642-15649, 1997.
11. Childs TJ, Watson MH, Sanghera JS, Campbell DL, Pelech SL, Mak AS. Phosphorylation of smooth muscle caldesmon by mitogen-activated protein (MAP) kinase and expression of MAP kinase in differentiated smooth muscle cells. J Biol Chem 267: 22853-22859, 1992.
12. Choi SK, Galan M, Kassan M, Partyka M, Trebak M, Matrougui K. Poly(adp-ribose) polymerase 1 inhibition improves coronary arteriole function in type 2 diabetes mellitus. Hypertension 59: 1060-1068, 2012.
13. Choi SK, Galan M, Partyka M, Trebak M, Belmadani S, Matrougui K. Chronic inhibition of epidermal growth factor receptor tyrosine kinase and extracellular signal-regulated kinases 1 and 2 (erk1/2) augments vascular response to limb ischemia in type 2 diabetic mice. Am J Pathol 180: 410-418, 2012.
14. Datla SR, Peshavariya H, Dusting GJ, Mahadev K, Goldstein BJ, Jiang F. Important role of Nox4 type NADPH oxidase in angiogenic responses in human microvascular endothelial cells in vitro. Arterioscler Thromb Vasc Biol 27: 2319-2324, 2007.
15. Dessy C, Kim I, Sougnez CL, Laporte R, Morgan KG. A role for MAP kinase in differentiated smooth muscle contraction evoked by β-adrenoceptor stimulation. Am J Physiol Cell Physiol 275: C1081-C1086, 1998.
16. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 23: 599-622, 2002.
17. Gao X, Zhang H, Schmidt AM, Zhang C. AGE/RAGE produces endothelial dysfunction in coronary arterioles in type 2 diabetic mice. Am J Physiol Heart Circ Physiol 295: H491-H498, 2008.
18. Go YM, Gipp JJ, Mulcahy RT, Jones DP. H2O2-dependent activation of GCLC-ARE4 reporter occurs by mitogen-activated protein kinase pathways without oxidation of cellular glutathione or thioredoxin-1. J Biol Chem 279: 5837-5845, 2004.
19. Gorin Y, Ricono JM, Kim NH, Bhandari B, Choudhury GG, Abboud HE. Nox4 mediates angiotensin II-induced activation of Akt/protein kinase B in mesangial cells. Am J Physiol Renal Physiol 285: F219-F229, 2003.
20. Hayaishi-Okano R, Yamasaki Y, Kajimoto Y, Sakamoto K, Ohtoshi K, Katakami N, Kawamori D, Miyatsuka T, Hatazaki M, Hazama Y, Hori M. Association of NAD(P)H oxidase p22 phox gene variation with advanced carotid atherosclerosis in Japanese type 2 diabetes. Diabetes Care 26: 458-463, 2003.
21. Hedges JC, Oxhorn BC, Carty M, Adam LP, Yamboliev IA, Gerthoffer WT. Phosphorylation of caldesmon by ERK MAP kinases in smooth muscle. Am J Physiol Cell Physiol 278: C718-C726, 2000.
22. Huang A, Yang YM, Yan C, Kaley G, Hintze TH, Sun D. Altered MAPK signaling in progressive deterioration of endothelial function in diabetic mice. Diabetes 61: 3181-3188, 2012.
23. Jiang F, Drummond GR, Dusting GJ. Suppression of oxidative stress in the endothelium and vascular wall. Endothelium 11: 79-88, 2004.
24. Kim YK, Lee MS, Son SM, Kim IJ, Lee WS, Rhim BY, Hong KW, Kim CD. Vascular NADH oxidase is involved in impaired endotheliumdependent vasodilation in OLETF rats, a model of type 2 diabetes. Diabetes 51: 522-527, 2002.
25. Lagaud GJ, Masih-Khan E, Kai S, van Breemen C, Dube GP. Influence of type ii diabetes on arterial tone and endothelial function in murine mesenteric resistance arteries. J Vasc Res 38: 578-589, 2001.
26. Lal AS, Clifton AD, Rouse J, Segal AW, Cohen P. Activation of the neutrophil NADPH oxidase is inhibited by SB 203580, a specific inhibitor of SAPK2/p38. Biochem Biophys Res Commun 259: 465-470, 1999.
27. Lopez-Lopez JG, Moral-Sanz J, Frazziano G, Gomez-Villalobos MJ, Flores-Hernandez J, Monjaraz E, Cogolludo A, Perez-Vizcaino F. Diabetes induces pulmonary artery endothelial dysfunction by NADPH oxidase induction. Am J Physiol Lung Cell Mol Physiol 295: L727-L732, 2008.
28. Matsumoto T, Kobayashi T, Ishida K, Taguchi K, Kamata K. Enhancement of mesenteric artery contraction to 5-HT depends on Rho kinase and Src kinase pathways in the ob/ob mouse model of type 2 diabetes. Br J Pharmacol 160: 1092-1104, 2010.
29. Matsumoto T, Kobayashi T, Wachi H, Seyama Y, Kamata K. Vascular nad(p)h oxidase mediates endothelial dysfunction in basilar arteries from otsuka long-evans tokushima fatty (oletf) rats. Atherosclerosis 192: 15-24, 2007.
30. McCall TB, Boughton-Smith NK, Palmer RM, Whittle BJ, Moncada S. Synthesis of nitric oxide from L-arginine by neutrophils. Release and interaction with superoxide anion. Biochem J 261: 293-296, 1989.
31. Modlinger P, Chabrashvili T, Gill PS, Mendonca M, Harrison DG, Griendling KK, Li M, Raggio J, Wellstein A, Chen Y, Welch WJ, Wilcox CS. RNA silencing in vivo reveals role of p22phox in rat angiotensin slow pressor response. Hypertension 47: 238-244, 2006.
32. O'Brien SF, McKendrick JD, Radomski MW, Davidge ST, Russell JC. Vascular wall reactivity in conductance and resistance arteries: differential effects of insulin resistance. Can J Physiol Pharmacol 76: 72-76, 1998.
33. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87: 315-424, 2007.
34. Pannirselvam M, Verma S, Anderson TJ, Triggle CR. Cellular basis of endothelial dysfunction in small mesenteric arteries from spontaneously diabetic (db/db-/-) mice: role of decreased tetrahydrobiopterin bioavailability. Br J Pharmacol 136: 255-263, 2002.
35. Paravicini TM, Touyz RM. NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. Diabetes Care 31: S170-S180, 2008.
36. Pieper GM. Review of alterations in endothelial nitric oxide production in diabetes: protective role of arginine on endothelial dysfunction. Hypertension 31: 1047-1060, 1998.
37. Rajesh M, Mukhopadhyay P, Bátkai S, Patel V, Saito K, Matsumoto S, Kashiwaya Y, Horváth B, Mukhopadhyay B, Becker L, Haskó G, Liaudet L, Wink DA, Veves A, Mechoulam R, Pacher P. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol 56: 2115-2125, 2010.
38. Rask-Madsen C, King GL. Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab 3: 46-56, 2007.
39. Rygiel TP, Mertens AE, Strumane K, van der Kammen R, Collard JG. The Rac activator Tiam1 prevents keratinocyte apoptosis by controlling ROS-mediated ERK phosphorylation. J Cell Sci 121: 1183-1192, 2008.
40. Schächinger V, Britten MB, Dimmeler S, Zeiher AM. NADH/NADPH oxidase p22 phox gene polymorphism is associated with improved coronary endothelial vasodilator function. Eur Heart J 22: 96-101, 2001.
41. Scotland RS, Chauhan S, Vallance PJ, Ahluwalia A. An endotheliumderived hyperpolarizing factor-like factor moderates myogenic constriction of mesenteric resistance arteries in the absence of endothelial nitric oxide synthase-derived nitric oxide. Hypertension 38: 833-839, 2001.
42. Son Y, Cheong YK, Kim NH, Chung HT, Kang DG, Pae HO. Mitogen-activated protein kinases and reactive oxygen species: how Can ROS activate MAPK pathways? J Signal Transduct 2011: 792639, 2011.
43. Srinivasan K, Ramarao P. Animal models in type 2 diabetes research: an overview. Indian J Med Res 125: 451-472, 2007.
44. Tan KC, Chow WS, Ai VH, Lam KS. Effects of angiotensin II receptor antagonist on endothelial vasomotor function and urinary albumin excretion in type 2 diabetic patients with microalbuminuria. Diabetes Metab Res Rev 18: 71-76, 2002.
45. Tan Y, Ichikawa T, Li J, Si Q, Yang H, Chen X, Goldblatt CS, Meyer CJ, Li X, Cai L, Cui T. Diabetic downregulation of Nrf2 activity via ERK contributes to oxidative stress-induced insulin resistance in cardiac cells in vitro and in vivo. Diabetes 60: 625-633, 2011.
46. Tojo A, Onozato ML, Kobayashi N, Goto A, Matsuoka H, Fujita T. Anti-oxidative effect of p38 mitogen-activated protein kinase inhibitor in the kidney of hypertensive rat. J Hypertens 23: 165-174, 2005.
47. Ulu N, Gurdal H, Landheer SW, Duin M, Guc MO, Buikema H, Henning RH. 1-Adrenoceptor-mediated contraction of rat aorta is partly mediated via transactivation of the epidermal growth factor receptor. Br J Pharmacol 161: 1301-1310, 2010.
48. Wang HD, Xu S, Johns DG, Du Y, Quinn MT, Cayatte AJ, Cohen RA. Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to angiotensin II in mice. Circ Res 88: 947-953, 2001.
49. Weerackody RP, Welsh DJ, Wadsworth RM, Peacock AJ. Inhibition of p38 MAPK reverses hypoxia-induced pulmonary artery endothelial dysfunction. Am J Physiol Heart Circ Physiol 296: H1312-H1320, 2009.
50. Westermann D, Rutschow S, Van Linthout S, Linderer A, Bücker-Gärtner C, Sobirey M, Riad A, Pauschinger M, Schultheiss HP, Tschöpe C. Inhibition of p38 mitogen-activated protein kinase attenuates left ventricular dysfunction by mediating pro-inflammatory cardiac cytokine levels in a mouse model of diabetes mellitus. Diabetologia 49: 2507-2513, 2006.